| NUSINERSEN SODIUM | None | ||
| 12MG/5ML |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. | |||
|
Yes
| |||
| SPINRAZA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||
| ****** ******** ******* (***) ********* *** ********* ** **** ****** **** ********** ********* | ************ *** ******* *** ********** ** **** ******** | ************ *** ******* *** ********** ** **** ******** ** * ******* | ************ *** ******* *** ********** ** **** ******** ** * ******* | ************ *** ******* *** ********** ** **** ******** ** * ******* | ******* *** ******** ****** ******** ******* | ************ *** ******* *** ********* ** *** ******* ** * ******* *** ********* ** * ******* | ********** ********* ****** ********** ********** (*) **** *'*** * ************* | ********** ** ******** ******** ** ********* ********** ** **** ********** | **************** ********** *′-*-******** ******* | ****** ******** ******* (***) ********* *** ********* ** **** ****** **** ********** ********* | ****** ******** ******* (***) ********* *** ********* ** **** ****** **** ********** ********* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|